Test performance of faecal occult blood testing for the detection of bowel cancer in people with chronic kidney disease (DETECT) protocol
| Autor: | Angela C Webster, Andrew Hayen, Richard D. M. Allen, Narelle Williams, Carol A. Pollock, Richard L. Hope, Anh Kieu, Simon D. Roger, Petra Macaskill, Germaine Wong, Allison Tong, Steven J. Chadban, Michael J. Bourke, Jonathan C. Craig, Kirsten Howard, Jeremy R. Chapman |
|---|---|
| Přispěvatelé: | Wong, Germaine, Howard, Kirsten, Chapman, Jeremy R, Tong, Allison, Bourke, Michael J, Hayen, Andrew, MacAskill, Petra, Hope, Richard L, Williams, Narelle, Kieu, Anh, Allen, Richard, Chadban, Steven, Pollock, Carol, Webster, Angela, Roger, Simon D, Craig, Jonathan C |
| Rok vydání: | 2011 |
| Předmět: |
Adult
medicine.medical_specialty Colorectal cancer Population 030232 urology & nephrology Comorbidity Interviews as Topic Study Protocol 03 medical and health sciences Feces Outcome Assessment (Health Care) 0302 clinical medicine Clinical Protocols Cancer screening Epidemiology Outcome Assessment Health Care medicine Humans 030212 general & internal medicine Intensive care medicine education Diagnostic Techniques and Procedures Aged education.field_of_study business.industry lcsh:Public aspects of medicine Clinical study design Public Health Environmental and Occupational Health Cancer lcsh:RA1-1270 Patient Preference Middle Aged medicine.disease kidney failure 3. Good health Clinical trial Occult Blood Physical therapy Kidney Failure Chronic diagnostic procedure Public Health business Colorectal Neoplasms clinical protocol chronic kidney disease colorectal tumor Kidney disease |
| Zdroj: | BMC Public Health BMC Public Health, Vol 11, Iss 1, p 516 (2011) |
| Popis: | Background Cancer is a major cause of mortality and morbidity in patients with chronic kidney disease (CKD). In patients without kidney disease, screening is a major strategy for reducing the risk of cancer and improving the health outcomes for those who developed cancers by detecting treatable cancers at an early stage. Among those with CKD, the effectiveness, the efficacy and patients' preferences for cancer screening are unknown. Methods/Design This work describes the protocol for the DETECT study examining the effectiveness, efficiency and patient's perspectives of colorectal cancer screening using immunochemical faecal occult blood testing (iFOBT) for people with CKD. The aims of the DETECT study are 1) to determine the test performance characteristics of iFOBT screening in individuals with CKD, 2) to estimate the incremental costs and health benefits of iFOBT screening in CKD compared to no screening and 3) to elicit patients' perspective for colorectal cancer screening in the CKD population. Three different study designs will be used to explore the uncertainties surrounding colorectal cancer screening in CKD. A diagnostic test accuracy study of iFOBT screening will be conducted across all stages of CKD in patients ages 35-70. Using individually collected direct healthcare costs and outcomes from the diagnostic test accuracy study, cost-utility and cost-effective analyses will be performed to estimate the costs and health benefits of iFOBT screening in CKD. Qualitative in-depth interviews will be undertaken in a subset of participants from the diagnostic test accuracy study to investigate the perspectives, experiences, attitudes and beliefs about colorectal cancer screening among individuals with CKD. Discussion The DETECT study will target the three major unknowns about early cancer detection in CKD. Findings from our study will provide accurate and definitive estimates of screening efficacy and efficiency for colorectal cancer, and will allow better service planning and budgeting for early cancer detection in this at-risk population. The DETECT study is also registered with the Australia New Zealand Clinical Trials Registry ACTRN12611000538943 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|